Last update 01 Nov 2024

Adnexitis

Last update 01 Nov 2024

Basic Info

Synonyms

ADNEXITIS, Adnexitis, Uterine Adnexitis

+ [4]

Introduction

Inflammation of the uterine appendages (ADNEXA UTERI) including infection of the FALLOPIAN TUBES (SALPINGITIS), the ovaries (OOPHORITIS), or the supporting ligaments (PARAMETRITIS).

Drugs associated with Adnexitis

Levofloxacin

Target

Bacterial Top II

Mechanism

Bacterial Top II inhibitors

Active Org.

CHIESI Farmaceutici SpA [+5]

Originator Org.

Johnson & Johnson

Active Indication

Otitis Externa [+31]

Inactive Indication

Abscess [+36]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date20 Dec 1996

Cefozopran Hydrochloride

Target

PBPs

Mechanism

PBPs inhibitors [+1]

Active Org.

Teva Takeda Yakuhin Ltd. [+1]

Originator Org.

Takeda Pharmaceutical Co., Ltd.

Active Indication

Bacterial Infections [+16]

Inactive Indication

(non-specific) purulent meningitis [+10]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Aug 1995

Cefdinir

Target

PBPs

Mechanism

PBPs inhibitors [+1]

Active Org.

LTL Pharma Co., Ltd. [+5]

Originator Org.

Astellas Pharma, Inc.

Active Indication

Bronchitis [+10]

Inactive Indication

Acute Bronchitis [+26]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.-

First Approval Date01 Jan 1991

Clinical Trials associated with Adnexitis

CTR20242493 / CompletedNot Applicable

头孢地尼分散片单中心、单剂量、随机、开放、两制剂、两周期、交叉、空腹及餐后生物等效性研究

[Translation] A single-center, single-dose, randomized, open-label, two-formulation, two-period, crossover, fasting and fed bioequivalence study of cefdinir dispersible tablets

主要目的：评估试验制剂头孢地尼分散片100mg和参比制剂头孢地尼胶囊（商品名：Cefzon®）100mg健康成年受试者空腹和餐后状态的生物等效性。次要目的：观察试验制剂和参比制剂在健康受试者中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of the test preparation, Cefdinir dispersible tablets 100 mg, and the reference preparation, Cefdinir capsules (trade name: Cefzon®) 100 mg, in healthy adult subjects in the fasting and fed state. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date12 Aug 2024

Sponsor / Collaborator

Hainan Rizhongtian Pharmaceutical Co., Ltd.

CTR20240387 / CompletedNot Applicable

头孢地尼胶囊人体生物等效性研究

[Translation] Study on the bioequivalence of cefdinir capsules in healthy volunteers

主要目的：本试验旨在研究单次空腹和餐后口服四川合信药业有限责任公司生产，重庆吉斯瑞制药有限责任公司持证的头孢地尼胶囊（0.1 g）的药代动力学特征；以CHOSEIDO PHARMACEUTICAL CO.,LTD. KAWAUCHI FACTORY生产的头孢地尼胶囊（全泽复®，0.1 g）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。次要目的：观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Primary objective: This study aims to study the pharmacokinetic characteristics of single fasting and postprandial oral administration of Cefdinir Capsules (0.1 g) produced by Sichuan Hexin Pharmaceutical Co., Ltd. and licensed by Chongqing Jisrui Pharmaceutical Co., Ltd.; Cefdinir Capsules (Quanzefu®, 0.1 g) produced by CHOSEIDO PHARMACEUTICAL CO., LTD. KAWAUCHI FACTORY were used as reference preparations to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations and evaluate the bioequivalence of the two preparations in humans. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date02 Mar 2024

Sponsor / Collaborator

Chongqing Jisiri Pharmaceutical Co., Ltd.

CTR20230144 / TerminatedNot Applicable

头孢地尼分散片单中心、单剂量、随机、开放、两制剂、两周期、交叉、空腹及餐后生物等效性研究

[Translation] A single-center, single-dose, randomized, open-label, two-formulation, two-period, crossover, fasting and fed bioequivalence study of cefdinir dispersible tablets

[Translation]

Start Date14 Mar 2023

Sponsor / Collaborator

Hainan Rizhongtian Pharmaceutical Co., Ltd.

100 Clinical Results associated with Adnexitis

100 Translational Medicine associated with Adnexitis

0 Patents (Medical) associated with Adnexitis

458

Literatures (Medical) associated with Adnexitis

30 Jun 2024·Ortopedia Traumatologia Rehabilitacja

Subacute Osteomyelitis of the Symphysis Pubis After Left Oophoritis Caused by Pseudomonas Aeruginosa. A Case Report

Article

Author: Murtezani, Ardiana ; Haxhija, Emir Q. ; Sllamniku, Sabit

Osteomyelitis of the symphysis pubis is a rarely described bone infection. The main strain of bacteria causing this infection is Staphylococcus aureus, while Pseudomonas aeruginosa is seen most commonly in intravenous drug users. Symmetrical involvement of both pubic bones is usually present. Osteomyelitis of the pubic bones following genital infections in females without a history of previous surgery is very unusual. We present a 47-year-old female patient who, to our best knowledge, is the first case in the literature to develop osteomyelitis of the pubic symphysis after adnexitis caused by Pseudomonas aeruginosa without having had previous surgery in that region.

01 Feb 2024·Wiadomości Lekarskie

Analysis of cases of premature rupture of membranes and preterm births to identify effective management measures to prevent them

Article

Author: Skrypchenko, Nataliia Y ; Lozova, Liliia A

Aim: Based on retrospective analysis recognize the key factors of development of premature childbirth and elaborate highly specific criteria for individual prognosis to improve perinatal outcomes. Materials and Methods: A retrospective analysis of the birth histories of 250 women and their newborns with spontaneous preterm births at 22-36 weeks was conducted using archival data from the department for pregnant women with obstetric pathology of the State Institution “Institute of Pediatrics, Obstetrics and Gynecology named by academician OM Lukianova of the National Academy of Medical Sciences of Ukraine” Results: Important risk factors for premature rupture of membranes (PROM) in preterm pregnancy include the presence of sexually transmitted diseases (χ2=31.188, p=0.001), bacterial vaginosis (χ2=30.913, p=0.0001), a history of abortion and/or preterm birth (χ2=16.62, p=0.0002), SARS during pregnancy (χ2=16.444, p=0.0002), chronic adnexitis in anamnesis (χ2=11.522, p=0.0031), inflammatory cervical disease (χ2=11.437, p=0.0032), anaemia (χ2=10.815, p=0.0044), isthmic-cervical insufficiency (ІСІ) (χ2=10.345, p=0.0057), chronic pyelonephritis with exacerbation (χ2=9.16, p=0.01), smoking during pregnancy (χ2=10.815, p=0.0044). Conclusions: The results of a retrospective analysis of 250 cases of preterm birth at 22 to 36 weeks allowed us to identify ways to effectively use existing diagnostic measures to determine readiness for pregnancy and the possibility of prolonging pregnancy to the viability of the newborn. Ways to improve the prevention of preterm birth and the design of further research were identified.

01 Apr 2023·Georgian medical news

PREVALENCE OF CHLAMYDIA AMONG WOMEN IN PLACES OF DEPRIVATION OF LIBERTY.

Article

Author: Shcherbakova, Yu ; Dzhoraieva, S ; Osinskaya, T ; Zapolsky, M

The goal is to establish serological invasive markers of Chlamydia trachomatis in female prisoners and to analyse the risk factors for the spread of chlamydial infection in prisons in Ukraine. When studying a sample of 103 female prisoners (whose average age is 35.9 years), serological markers of Chlamydia trachomatis (immunoglobulin G) were analysed. Social characteristics of prisoners and risk factors for chlamydia spread have been analysed. Markers of Chlamydia trachomatis (class G immunoglobulins) were detected in serum of 37.8% of female prisoners. In the majority of cases, chlamydia was asymptomatic or in the form of chronic endocervicitis (53.8%), adnexitis (38.5%), and urethritis (17.9%), which was a mixed process with other STIs and HIV (HSV-1 (up to 100%), HSV-2 (30%), Treponema pallidum (26.6%), Ureaplasma urealyticum (6.6%), HBV (26.6%), HCV (33.3%), HIV (30%)). Identified infection risk factors: age over 25 years, HIV, HSV, HCV, HBV, and other STIs, endocervicitis, chronic pelvic pain, urethritis, risky sexual behaviour, drug use, alcoholism, prolonged or repeated confinement, absence of family. The prevalence of Chlamydia trachomatis among female prisoners in Ukraine (37.8%) is 2.5 times higher often and significantly higher (P<0.05) than among women with a predominance of chronic inflammatory diseases of the pelvic organs and significantly higher than in the general population (20.9 per 100,000).

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Adnexitis

Basic Info

Related

Analysis